Skip to main content

Aprea Therapeutics, Inc.

APRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001781983

No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Aprea Therapeutics, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of APRE: Q3 2025 compared with Q4 2025
MeasureQ3 2025Q4 2025Change
Holders2322−1
Shares1.62M1.70M+76.7K (+4.7%)
Value$2.39M$1.45M−$941.5K (−39.4%)

New holders (5)

Institutions that held Aprea Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to APRE in Q4 2025
InstitutionSharesValue% of portfolio
Murchinson Ltd.340,139$290.1K0.16%
DRW Securities, LLC120,651$102.9K0.01%
Citadel Advisors LLC51,041$43.5K0.00%
Jane Street Group, LLC46,621$39.8K0.00%
XTX Topco Ltd24,304$20.7K0.00%

Sold out (6)

Institutions that held Aprea Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of APRE in Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
DAFNA Capital Management LLC137,174$202.3K
Sio Capital Management, LLC112,223$165.5K
HRT Financial LP12,264$18.0K
Landscape Capital Management, L.L.C.10,496$15.5K
MB, Levis & Associates, LLC806$1.19K
Citigroup Inc5$7